Praluent recommended for approval to lower cholesterol

View source ↗

Summary

The European Medicines Agency recommended approval of Praluent (alirocumab) to lower cholesterol, pursuing a new indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)